Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Not surprising

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Dec 02, 2022 7:25pm

178 Views

Post# 35147973

RE:RE:RE:RE:RE:RE:RE:RE:Not surprising

If a more frequent but smaller dose is a valid way to reduce side effects, it should also reduce efficacy. I am not an expert in PK/PD, an Thera disclosed nothing about that, except their unclear 10% of free docetaxel. So I don't see clearly why more frequent but smaller dose would a efficious as the 300 mg/m2 dose. Add to that the fact that we have no idea of how much docetaxel really goes into cancer cells overexpressing sortilin in humans.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments